CARLSBAD, Calif. & MONTREAL--(BUSINESS WIRE)--A scientific collaboration aimed at advancing pharmacogenomics research through the development of novel methodologies and advanced reagents for targeted medical resequencing was announced today by Invitrogen Corporation (NASDAQ:IVGN), a provider of essential life science technologies for research, production and diagnostics, and the Génome Québec and Montreal Heart Institute Pharmacogenomics Centre, a provider of pharmacogenomics research, content, and services.
